PortfoliosLab logoPortfoliosLab logo
PFE vs. NVO
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

PFE vs. NVO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Pfizer Inc. (PFE) and Novo Nordisk A/S (NVO). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, PFE achieves a 8.62% return, which is significantly higher than NVO's -10.58% return. Over the past 10 years, PFE has underperformed NVO with an annualized return of 2.17%, while NVO has yielded a comparatively higher 7.06% annualized return.


PFE

1D
2.23%
1M
1.16%
YTD
8.62%
6M
4.84%
1Y
14.37%
3Y*
-7.54%
5Y*
-3.38%
10Y*
2.17%

NVO

1D
2.69%
1M
-6.47%
YTD
-10.58%
6M
-9.53%
1Y
-41.56%
3Y*
-15.73%
5Y*
2.96%
10Y*
7.06%
*Multi-year figures are annualized to reflect compound growth (CAGR)

PFE vs. NVO - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
PFE
Pfizer Inc.
8.62%0.65%-2.22%-41.26%-10.41%66.70%3.07%-6.91%24.82%15.90%
NVO
Novo Nordisk A/S
-10.58%-39.22%-15.93%54.84%22.66%63.52%23.33%28.70%-12.98%52.92%

Correlation

The correlation between PFE and NVO is 0.34, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.34

Correlation (3Y)
Calculated over the trailing 3-year period

0.24

Correlation (5Y)
Calculated over the trailing 5-year period

0.26

Correlation (10Y)
Calculated over the trailing 10-year period

0.30

Correlation (All Time)
Calculated using the full available price history since Jan 4, 1982

0.24

The correlation between PFE and NVO shifts across timeframes, from 0.24 (3 years) to 0.34 (1 year), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

PFE:

$149.98B

NVO:

$195.56B

EPS

PFE:

$1.31

NVO:

DKK 27.42

PE Ratio

PFE:

19.95

NVO:

10.37

PEG Ratio

PFE:

0.36

NVO:

0.44

PS Ratio

PFE:

2.36

NVO:

3.86

PB Ratio

PFE:

1.66

NVO:

6.23

Total Revenue (TTM)

PFE:

$63.32B

NVO:

DKK 327.80B

Gross Profit (TTM)

PFE:

$43.91B

NVO:

DKK 268.30B

EBITDA (TTM)

PFE:

$16.94B

NVO:

DKK 181.54B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

PFE vs. NVO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PFE
PFE Risk / Return Rank: 6363
Overall Rank
PFE Sharpe Ratio Rank: 6464
Sharpe Ratio Rank
PFE Sortino Ratio Rank: 5959
Sortino Ratio Rank
PFE Omega Ratio Rank: 5757
Omega Ratio Rank
PFE Calmar Ratio Rank: 6969
Calmar Ratio Rank
PFE Martin Ratio Rank: 6666
Martin Ratio Rank

NVO
NVO Risk / Return Rank: 1414
Overall Rank
NVO Sharpe Ratio Rank: 1010
Sharpe Ratio Rank
NVO Sortino Ratio Rank: 1313
Sortino Ratio Rank
NVO Omega Ratio Rank: 1111
Omega Ratio Rank
NVO Calmar Ratio Rank: 1414
Calmar Ratio Rank
NVO Martin Ratio Rank: 2020
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

PFE vs. NVO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Pfizer Inc. (PFE) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


PFENVODifference
Sharpe ratioReturn per unit of total volatility

+1.41

Sortino ratioReturn per unit of downside risk

+2.04

Omega ratioGain probability vs. loss probability

1.13

0.86

+0.27

Calmar ratioReturn relative to maximum drawdown

1.26

-0.76

+2.02

Martin ratioReturn relative to average drawdown

2.54

-1.11

+3.64

PFE vs. NVO - Sharpe Ratio Comparison

The current PFE Sharpe Ratio is 0.61, which is higher than the NVO Sharpe Ratio of -0.80. The chart below compares the historical Sharpe Ratios of PFE and NVO, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

PFE vs. NVO - Drawdown Comparison

The maximum PFE drawdown since its inception was -69.24%, smaller than the maximum NVO drawdown of -74.70%. Use the drawdown chart below to compare losses from any high point for PFE and NVO.


Loading charts...

Drawdown Indicators


PFENVODifference

Max Drawdown

Largest peak-to-trough decline

-69.24%

-74.70%

+5.46%

Max Drawdown (1Y)

Largest decline over 1 year

-11.47%

-55.03%

+43.56%

Max Drawdown (3Y)

Largest decline over 3 years

-40.75%

-74.70%

+33.95%

Max Drawdown (5Y)

Largest decline over 5 years

-58.96%

-74.70%

+15.74%

Max Drawdown (10Y)

Largest decline over 10 years

-58.96%

-74.70%

+15.74%

Current Drawdown

Current decline from peak

-45.76%

-68.06%

+22.30%

Average Drawdown

Average peak-to-trough decline

-22.90%

-17.78%

-5.12%

Ulcer Index

Depth and duration of drawdowns from previous peaks

5.68%

37.52%

-31.84%

Volatility

PFE vs. NVO - Volatility Comparison

The current volatility for Pfizer Inc. (PFE) is 5.08%, while Novo Nordisk A/S (NVO) has a volatility of 10.69%. This indicates that PFE experiences smaller price fluctuations and is considered to be less risky than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


PFENVODifference

Volatility (1M)

Calculated over the trailing 1-month period

5.08%

10.69%

-5.61%

Volatility (6M)

Calculated over the trailing 6-month period

14.72%

38.46%

-23.74%

Volatility (1Y)

Calculated over the trailing 1-year period

23.85%

51.88%

-28.03%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

25.49%

38.34%

-12.85%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

23.89%

32.56%

-8.67%

Dividends

PFE vs. NVO - Dividend Comparison

PFE's dividend yield for the trailing twelve months is around 6.57%, more than NVO's 4.10% yield.


PositionTTM20252024202320222021202020192018201720162015
NVO
Novo Nordisk A/S
4.10%3.31%1.68%1.00%1.20%1.35%1.87%2.14%1.45%1.52%2.87%0.92%
PFE
Pfizer Inc.
6.57%6.91%6.33%5.70%3.12%2.64%3.92%3.68%3.12%3.53%3.69%3.47%

Financials

PFE vs. NVO - Financials Comparison

This section allows you to compare key financial metrics between Pfizer Inc. and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


20.00B40.00B60.00B80.00B100.00B20222023202420252026
14.45B
96.82B
(PFE) Total Revenue
(NVO) Total Revenue
Please note, different currencies. PFE values in USD, NVO values in DKK

PFE vs. NVO - Profitability Comparison

The chart below illustrates the profitability comparison between Pfizer Inc. and Novo Nordisk A/S over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

20.0%30.0%40.0%50.0%60.0%70.0%80.0%90.0%20222023202420252026
67.3%
86.0%
Portfolio components
PFE - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Pfizer Inc. reported a gross profit of 9.72B and revenue of 14.45B. Therefore, the gross margin over that period was 67.3%.

NVO - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported a gross profit of 83.23B and revenue of 96.82B. Therefore, the gross margin over that period was 86.0%.

PFE - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Pfizer Inc. reported an operating income of 4.03B and revenue of 14.45B, resulting in an operating margin of 27.9%.

NVO - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported an operating income of 59.62B and revenue of 96.82B, resulting in an operating margin of 61.6%.

PFE - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Pfizer Inc. reported a net income of 2.69B and revenue of 14.45B, resulting in a net margin of 18.6%.

NVO - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported a net income of 48.56B and revenue of 96.82B, resulting in a net margin of 50.2%.


Frequently Asked Questions


PFE and NVO have a correlation of 0.34, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

NVO has higher volatility (10.69%) compared to PFE (5.08%). In terms of maximum drawdown, PFE dropped -69.24% vs NVO's -74.70%.

PFE currently has the higher Sharpe Ratio (0.61 vs -0.80), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for PFE and NVO

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer